ARQT

SEC source: 0001567619-20-015772 · doc1.xml · nonDerivative · entry 1

Welgus Howard G. · CIK 0001801050 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,178

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares.

SEC source: 0001567619-20-015690 · doc1.xml · derivative · entry 3

Welgus Howard G. · CIK 0001801050 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,550

Underlying: Common Stock · 6,110 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares.

F3 · derivative.exercise_date: The option vests monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

SEC source: 0001567619-20-015690 · doc1.xml · nonDerivative · entry 1

Welgus Howard G. · CIK 0001801050 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,102

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares.

SEC source: 0001567619-20-014338 · doc1.xml · derivative · entry 2

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 320,000

Underlying: Common Stock · 320,000 shares

Expires 2030-08-03

F3 · derivative.exercise_date: The option vests as to 1/4 of the total shares on August 1, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested on August 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001567619-20-014338 · doc1.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,500

F1 · shares: Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.

F2 · balance_after: Includes 33,500 RSUs. The RSUs will begin vesting upon the achievement of the performance-based milestones.

SEC source: 0001567619-20-014341 · doc1.xml · derivative · entry 7

Welgus Howard G. · CIK 0001801050 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,419

Underlying: Common Stock · 67 shares

Expires 2029-03-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F4 · derivative.exercise_date: The option vests monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

SEC source: 0001567619-20-014341 · doc1.xml · derivative · entry 6

Welgus Howard G. · CIK 0001801050 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,010

Underlying: Common Stock · 2,733 shares

Expires 2029-03-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F4 · derivative.exercise_date: The option vests monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

SEC source: 0001567619-20-014341 · doc1.xml · nonDerivative · entry 4

Welgus Howard G. · CIK 0001801050 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,992

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The transaction was executed in multiple trades in prices ranging from $25.22 to $25.94, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-20-014341 · doc1.xml · nonDerivative · entry 3

Welgus Howard G. · CIK 0001801050 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,059

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001567619-20-014341 · doc1.xml · nonDerivative · entry 2

Welgus Howard G. · CIK 0001801050 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,992

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The transaction was executed in multiple trades in prices ranging from $25.22 to $25.94, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-20-014341 · doc1.xml · nonDerivative · entry 1

Welgus Howard G. · CIK 0001801050 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,725

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001567619-20-012131 · doc1.xml · derivative · entry 2

Smither John W · CIK 0001559583 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,080

Underlying: Common Stock · 14,875 shares

Expires 2029-05-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares.

F3 · derivative.exercise_date: The option vests as to 1/4 of the total shares on May 1, 2020, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on May 1, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

SEC source: 0001567619-20-012131 · doc1.xml · nonDerivative · entry 1

Smither John W · CIK 0001559583 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,840

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares.

F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024.

SEC source: 0001567619-21-004119 · doc1.xml · nonDerivative · entry 1

Lock Kenneth A. · CIK 0001801047 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,100

F1 · kind: Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan.

F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.

SEC source: 0001567619-21-004118 · doc1.xml · nonDerivative · entry 1

Turney Patricia A. · CIK 0001801045 · SVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,205

F1 · kind: Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan.

F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.

SEC source: 0001567619-20-008827 · doc1.xml · derivative · entry 1

Gilbert Halley E · CIK 0001601360 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2030-05-01

F1 · derivative.exercise_date: The option vests as to 1/3 of the total shares on each of May 1, 2021, May 1, 2022 and May 1, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001567619-20-006469 · doc1.xml · derivative · entry 6

Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,492

Underlying: Common Stock · 59,481 shares

Expires 2029-03-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction by the Reporting Person is an exercise of an in-the-money option for cash consideration and does not involve the sale of any shares.

F6 · derivative.exercise_date: The option vests monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

SEC source: 0001567619-20-006469 · doc1.xml · nonDerivative · entry 1

Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 566,928

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction by the Reporting Person is an exercise of an in-the-money option for cash consideration and does not involve the sale of any shares.

SEC source: 0001567619-20-006468 · doc1.xml · derivative · entry 3

Welgus Howard G. · CIK 0001801050 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,660

Underlying: Common Stock · 6,110 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction by the Reporting Person is an exercise of an in-the-money option for cash consideration and does not involve the sale of any shares.

F3 · derivative.exercise_date: The option vests monthly over 35 months beginning July 11, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

SEC source: 0001567619-20-006468 · doc1.xml · nonDerivative · entry 1

Welgus Howard G. · CIK 0001801050 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction by the Reporting Person is an exercise of an in-the-money option for cash consideration and does not involve the sale of any shares.

SEC source: 0001567619-20-005549 · doc1.xml · derivative · entry 1

SILVERSTEIN JONATHAN · CIK 0001171005 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2030-02-27

F1 · derivative.exercise_date: The option vests and becomes exercisable 100% on the earlier of the date of the next annual meeting of the Issuer's stockholders or February 27, 2021.

SEC source: 0001567619-20-005543 · doc1.xml · derivative · entry 1

CHAUDHURI BHASKAR · CIK 0001458643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2030-02-27

F1 · derivative.exercise_date: The option vests and becomes exercisable 100% on the earlier of the date of the next annual meeting of the Issuer's stockholders or February 27, 2021.

SEC source: 0001567619-20-005548 · doc1.xml · derivative · entry 4

OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2030-02-27

F5 · derivative.exercise_date: The shares subject to the stock option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024.

SEC source: 0001567619-20-005548 · doc1.xml · nonDerivative · entry 1

OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 279,279

F1 · shares: Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.

F2 · balance_after: Includes 9,000 RSUs. The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024.

SEC source: 0001567619-20-005545 · doc1.xml · derivative · entry 1

Heron Patrick J · CIK 0001365617 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2030-02-27

F1 · derivative.exercise_date: The option vests and becomes exercisable 100% on the earlier of the date of the next annual meeting of the Issuer's stockholders or February 27, 2021.

SEC source: 0001567619-20-005550 · doc1.xml · derivative · entry 2

Smither John W · CIK 0001559583 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2030-02-27

F3 · derivative.exercise_date: The shares subject to the stock option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024.

SEC source: 0001567619-20-005550 · doc1.xml · nonDerivative · entry 1

Smither John W · CIK 0001559583 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,965

F1 · shares: Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.

F2 · balance_after: Includes 9,000 RSUs. The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024.

SEC source: 0001567619-20-005544 · doc1.xml · derivative · entry 1

ESTES DANIEL · CIK 0001702527 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2030-02-27

F1 · derivative.exercise_date: The option vests and becomes exercisable 100% on the earlier of the date of the next annual meeting of the Issuer's stockholders or February 27, 2021.

SEC source: 0001567619-20-005553 · doc1.xml · derivative · entry 3

Welgus Howard G. · CIK 0001801050 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2030-02-27

F4 · derivative.exercise_date: The shares subject to the stock option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024.

SEC source: 0001567619-20-005553 · doc1.xml · nonDerivative · entry 1

Welgus Howard G. · CIK 0001801050 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,882

F1 · shares: Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.

F2 · balance_after: Includes 9,000 RSUs. The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024.

SEC source: 0001567619-20-005552 · doc1.xml · derivative · entry 6

Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2030-02-27

F7 · derivative.exercise_date: The shares subject to the stock option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024.

SEC source: 0001567619-20-005552 · doc1.xml · nonDerivative · entry 1

Watanabe Todd Franklin · CIK 0001801061 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 507,447

F1 · shares: Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.

F2 · balance_after: Includes 29,000 RSUs. The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024.

SEC source: 0001567619-20-005551 · doc1.xml · derivative · entry 2

Turney Patricia A. · CIK 0001801045 · Senior VP, Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common · 27,000 shares

Expires 2030-03-27

F3 · derivative.exercise_date: The shares subject to the stock option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024.

SEC source: 0001567619-20-005551 · doc1.xml · nonDerivative · entry 1

Turney Patricia A. · CIK 0001801045 · Senior VP, Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

F1 · shares: Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.

F2 · balance_after: Includes 9,000 RSUs. The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024.

SEC source: 0001567619-20-005547 · doc1.xml · derivative · entry 2

Lock Kenneth A. · CIK 0001801047 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2030-02-27

F3 · derivative.exercise_date: The shares subject to the stock option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024.

SEC source: 0001567619-20-005547 · doc1.xml · nonDerivative · entry 1

Lock Kenneth A. · CIK 0001801047 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

F1 · shares: Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.

F2 · balance_after: Includes 9,000 RSUs. The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024.

SEC source: 0000899243-20-006958 · doc4.xml · derivative · entry 1

Sun Ricky · CIK 0001790589 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2030-02-27

F1 · derivative.exercise_date: The option vests and becomes exercisable 100% on the earlier of the date of the next annual meeting of the Issuer's stockholders or February 27, 2021.

SEC source: 0000947871-20-000079 · ownership.xml · derivative · entry 8

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 429,786 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F6 · derivative.exercise_date: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F6 · derivative.expiration_date: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F4 · ownership.nature: The Shares are held of record by OrbiMed Partners Master Fund Limited ("OPMF"). OrbiMed Capital is the investment manager of OPMF and is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPMF.

SEC source: 0000947871-20-000079 · ownership.xml · derivative · entry 7

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 859,573 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F6 · derivative.exercise_date: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F6 · derivative.expiration_date: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC is the managing member of OPI VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Captial LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-20-000079 · ownership.xml · derivative · entry 6

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 2,825,603 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: The Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F5 · derivative.exercise_date: The Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F5 · derivative.expiration_date: The Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC is the managing member of OPI VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Captial LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-20-000079 · ownership.xml · nonDerivative · entry 5

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 606,286

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F4 · ownership.nature: The Shares are held of record by OrbiMed Partners Master Fund Limited ("OPMF"). OrbiMed Capital is the investment manager of OPMF and is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPMF.

SEC source: 0000947871-20-000079 · ownership.xml · nonDerivative · entry 4

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,067,564

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC is the managing member of OPI VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Captial LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-20-000079 · ownership.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,207,991

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: The Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC is the managing member of OPI VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Captial LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-20-000078 · ownership.xml · derivative · entry 8

SILVERSTEIN JONATHAN · CIK 0001171005 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 429,786 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F6 · derivative.exercise_date: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F6 · derivative.expiration_date: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F4 · ownership.nature: The Shares are held of record by OrbiMed Partners Master Fund Limited ("OPMF"). OrbiMed Capital is the investment manager of OPMF and is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and the Reporting Person, each of whom disclaims beneficial ownership of the Shares held by OPMF.

SEC source: 0000947871-20-000078 · ownership.xml · derivative · entry 7

SILVERSTEIN JONATHAN · CIK 0001171005 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 859,573 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F6 · derivative.exercise_date: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F6 · derivative.expiration_date: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC is the managing member of OPI VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Captial LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and the Reporting Person, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-20-000078 · ownership.xml · derivative · entry 6

SILVERSTEIN JONATHAN · CIK 0001171005 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 2,825,603 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: The Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F5 · derivative.exercise_date: The Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F5 · derivative.expiration_date: The Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC is the managing member of OPI VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Captial LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and the Reporting Person, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-20-000078 · ownership.xml · nonDerivative · entry 5

SILVERSTEIN JONATHAN · CIK 0001171005 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 606,286

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F4 · ownership.nature: The Shares are held of record by OrbiMed Partners Master Fund Limited ("OPMF"). OrbiMed Capital is the investment manager of OPMF and is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and the Reporting Person, each of whom disclaims beneficial ownership of the Shares held by OPMF.

SEC source: 0000947871-20-000078 · ownership.xml · nonDerivative · entry 4

SILVERSTEIN JONATHAN · CIK 0001171005 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,067,564

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: The Series C Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC is the managing member of OPI VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Captial LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and the Reporting Person, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-20-000078 · ownership.xml · nonDerivative · entry 3

SILVERSTEIN JONATHAN · CIK 0001171005 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,207,991

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: The Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII"), is the general partner of OPI VII and OrbiMed Advisors LLC is the managing member of OPI VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Captial LLC ("OrbiMed Capital") is a relying adviser of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and the Reporting Person, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F3 · ownership.nature: Each of OrbiMed GP VII, OrbiMed Capital, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-20-006599 · doc4.xml · derivative · entry 4

CHAUDHURI BHASKAR · CIK 0001458643 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Common Stock · 49,981 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.nature: The securities are held of record by The Chaudhuri Family Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.